Quantum BioPharma Ltd. (QNTM) Research
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Market snapshot
- Symbol
- QNTM
- Price
- $3.80
- Day change
- -4.28%
- Market cap
- $17.1M
- P/E ratio
- -0.55x
- 52-week range
- 2.07-38.25
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Next earnings
- in 2 months
Recent news
- Quantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Research
Quantum BioPharma stock momentum surges as MS study hits 50% enrollment and early PET imaging data shows promising results.
Peer companies
Open Quantum BioPharma Ltd. (QNTM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.